

1 **Title**

2 Comparative evaluation of plasma biomarkers of *Schistosoma haematobium* infection in
3 endemic populations from Burkina Faso

4 **Short title**

5 Plasma biomarkers of *Schistosoma haematobium* infection

6 **Authors**

7 Mireille Ouedraogo 1-2-3, Jana Christina Hey 4, Stan Hilt 5, Veronica Rodriguez Fernandez
8 1, Doris Winter 4, Ravo Razafindrakoto 6, Pytsje Hoekstra 5, Youssouf Kabore 3, Marco
9 Fornili 7, Laura Baglietto 7, Issa Nebie 3, Govert J van Dam 5, Paul L Corstjens 8, Daniela
10 Fusco 4-9, David Modiano 2, Fabrizio Bruschi 1, Valentina D Mangano 1

11 **Affiliations**

- 12 1. Dept. of Translational Research in Medicine and Surgery, University of Pisa, Italy
- 13 2. Dept. of Public Health and Infectious Diseases, University of Rome La Sapienza, Italy
- 14 3. Centre National de Recherche et Formation sur le Paludisme, Ouagadougou,
15 Burkina Faso
- 16 4. Dept. Infectious Diseases Epidemiology, Bernard Nocht Institute for Tropical
17 Medicine, Germany
- 18 5. Dept. of Parasitology, Leiden University Medical Center, the Netherlands
- 19 6. Centre d'infectiologie Charles Merieux, Antananarivo, Madagascar
- 20 7. Dept. of Clinical and Experimental Medicine, University of Pisa, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 8. Dept. of Cell & Chemical Biology, Leiden University Medical Center, the Netherlands

22 9. German Center for Infection Research, Hamburg - Lübeck - Borstel – Riems,

23 Germany

24 @ valentina.mangano@unipi.it

25 **Abstract**

26 Infection with *Schistosoma haematobium* causes urogenital disease associated with organ
27 dysfunction, bleeding, pain, and higher susceptibility to infections and cancer. Timely and
28 accurate diagnosis is crucial for prompt and appropriate treatment as well as surveillance
29 efforts, and the use of plasma biomarkers offers important advantages over parasitological
30 examination of urine, including increased sensitivity and the possibility to use the same
31 specimen for multiple investigations.

32 The present study aims to evaluate the diagnostic performance of different plasma
33 biomarkers in endemic populations from Burkina Faso, West Africa. *Schistosoma* spp.
34 Circulating Anodic Antigen (CAA), cell free *S. haematobium* DNA (cfDNA), class M and G
35 antibodies against *S. haematobium* Soluble Worm Antigen Preparation (SWAP) and Soluble
36 Egg Antigen (SEA) were measured in 406 plasma samples. Results of each biomarker test
37 were compared to those of CAA, a Composite Reference Standard (CRS) and Latent Class
38 Analysis (LCA).

39 An identical proportion of positive samples (29%) was observed as a result of CAA and cfDNA
40 testing, with a substantial agreement (84%, Cohen $k=0.62$) between the results of the two
41 tests, and a comparable agreement with the results of CRS and LCA. A higher positivity was

42 observed, as expected, as a result of specific antibody testing (47%-72%), with IgG showing
43 a higher agreement than IgM with the three references. Also, higher IgG levels were
44 observed in current vs past infection, and ROC analysis identified optimal cutoff values for
45 improved testing accuracy.

46 This study provides compelling evidence that can inform the choice of the most appropriate
47 diagnostic plasma biomarker for urogenital schistosomiasis in endemic areas, depending on
48 the purpose, context, and available resources for testing. Either CAA or cfDNA testing can
49 be used for the diagnosis of patients and for epidemiological investigations, even in absence
50 of urine filtration microscopy, whereas anti-SWAP or anti-SEA IgG can be employed for
51 surveillance and integrated monitoring of control interventions against poverty-associated
52 diseases.

53

54 **Keywords**

55 Schistosomiasis, *Schistosoma haematobium*, diagnosis, plasma biomarkers, Neglected

56 Tropical Diseases, Burkina Faso

57

58 **Author summary**

59 Urogenital schistosomiasis is a chronic debilitating disease affecting populations living in
60 Africa and the Middle East and showing a strong association with poverty. Accurate
61 detection of infection is important both for disease treatment and surveillance. Several tests

62 based on detection in plasma of parasite protein (CAA), parasite DNA or parasite-specific
63 host antibodies (IgM and IgG against SWAP and SEA antigens) are available and this study
64 aims at comparing them to evaluate their accuracy. The comparison showed that tests based
65 on parasite CAA or DNA yield very similar results and therefore the test of choice for
66 diagnosis or epidemiological investigations can be based on laboratory resources.
67 Additionally, the comparison showed that IgG against SWAP and SEA outperform IgM, and
68 that high accuracy can be achieved by identifying an optimal level to determine positivity
69 (cut-off), making these antibody tests ideal for surveillance purposes.

70

71 MAIN TEXT

72 Introduction

73 Human schistosomiasis is a poverty-associated parasitic diseases caused by trematode
74 blood flukes of the genus *Schistosoma*. It is estimated that 250 million people are infected
75 in 78 endemic countries, and that 90% of cases occur in Sub-Saharan Africa (SSA) [1-3].

76 *S. haematobium*, endemic in Africa and the Middle East, and since recent years in some areas
77 of Europe [4-6], is the only species causing urogenital disease. Infection occurs by contact
78 with fresh-water bodies infested with free-swimming cercariae larvae released by specific
79 intermediate snail hosts of the genus *Bulinus*. Cercariae penetrate the skin of the human
80 host, shed their fork and become schistosomula, which then migrate via venous circulation
81 to the lungs, the heart and the liver where they mature to the adult stage. Adult worms exit
82 the liver via the portal vein system and reach the venules of the bladder, where they
83 reproduce and gravid females lay eggs. While most eggs remain trapped in venules and
84 body tissues, some are eliminated with urine. When the human host discharges urine in
85 fresh-water bodies, the eggs hatch and release miracidia, which penetrate the snail host and
86 transform into sporocysts. After two generation of sporocysts larval reproduction, these
87 transform into cercariae, able to initiate a new transmission cycle [7-9].

88 The disease is mostly accounted by immunopathogenic responses to the worms' eggs
89 accumulated around bladder and ureters resulting in granuloma formation and tissue
90 fibrosis. Clinical manifestations include haematuria, obstructive uropathy, kidney damage
91 and squamous cell carcinoma [7-9]. In females, genital schistosomiasis (FGS) causes

92 ulcerative lesions and fibrosis in vagina, cervix and uterus, resulting in bleeding, pain and
93 higher risk of HIV infection [10-11]. Control of schistosomiasis mainly focuses on reducing
94 disease burden through periodic, large-scale population treatment with praziquantel, but
95 more comprehensive approaches include water, hygiene and sanitation strategies, health
96 education and snail control [2-3].

97 Diagnosis of schistosomiasis is fundamental for appropriate treatment of symptomatic
98 individuals as well as for monitoring the success of control efforts, and a variety of direct
99 (detecting the parasite or parasite molecules) and indirect (detecting the human immune
100 responses to the parasite) laboratory methods are available, each with different advantages
101 and disadvantages. Microscopic examination of urine samples (urine filtration microscopy)
102 for detection of *S. haematobium* eggs has optimal specificity based on distinct
103 morphological features. However, sensitivity is hampered by the irregular timing of eggs
104 release in urine and by their limited number, particularly in low intensity infections, and the
105 examination of at least three specimens is required [12-13]. Other direct methods include
106 the detection of intestinal antigens regurgitated by *Schistosoma* adult worms and therefore
107 released in circulation, namely Circulating Cathodic Antigen (CCA) and Circulating Anodic
108 Antigen (CAA), in either urine or serum/plasma samples by immunological assays such as
109 ELISA and ICT, including the point-of-care CCA (POC-CCA) test and the upconverting particle
110 lateral flow CAA (UCP-LF CAA) test [14]. Compared to CCA, CAA testing has shown a better
111 sensitivity for the diagnosis of infection by different *Schistosoma* species, including *S.*
112 *haematobium*, and in areas of low endemicity [15]. It has also been reported that CAA
113 concentration shows little day to day fluctuations, positively correlates with the number of

114 adult worms, and decreases sharply after drug treatment, establishing it as a valuable test
115 for both diagnosis and follow-up [16]. Nonetheless, it must be noted that infection with
116 larval stages cannot be diagnosed by such antigen tests. Detection of cell-free DNA (cfDNA)
117 of schistosomes in either stool/urine or plasma by molecular assays represents a promising
118 method for early direct diagnosis, since it can detect all stages of infection including larval
119 stages, and since optimal analytical sensitivity and specificity can be achieved by choice of
120 multi-copy specific targets [17]. For *S. haematobium*, Real Time PCR protocols based on the
121 detection of *Dra1*, a repeat sequence specific of this species and representing >15% of its
122 genome, have been recently developed and tested in migrant and travellers as well as
123 residents in endemic areas [18-22]. However, cfDNA may circulate for some time after
124 successful treatment and its detection might not therefore always indicate current infection
125 [17]. Regarding indirect methods, these are based on the detection of specific antibodies
126 against parasite antigens in serum/plasma samples by immunological methods such as
127 ELISA, ICT and more recently Luminex [23-24]. The main advantage of these methods is
128 increased sensitivity compared to urine filtration microscopy, as demonstrated in non-
129 endemic contexts [25-26]. However, as production of antibodies by plasma cells only starts
130 about 1 week after exposure to a given antigen, a temporal delay is to be expected between
131 infection and the detection of specific antibodies. More importantly, antibodies can still be
132 detectable in plasma after drug treatment and parasite death, both because of antigen
133 persistence and continued exposure to the immune system, and because of the long half-
134 life of class G immunoglobulins (Ig). Therefore, seropositivity might reflect either history of
135 infection or current infection or both. Antigens employed for *S. haematobium* serology have

136 long included soluble excretory/secretory products from the different stages, such as
137 Cercarial Antigen Preparation (CAP), Soluble Worm Adult Preparation (SEA) and Soluble Egg
138 Antigen (SEA) [21, 27], and, more recently, recombinant proteins of the tetraspanin family
139 that were identified as promising candidates through immunomic analyses [28-29]. It is
140 noteworthy that no commercial in vitro diagnostic tests for the specific diagnosis of *S.*
141 *haematobium* exist to date.

142 As described above, several assays are available for laboratory diagnosis of *S. haematobium*
143 using plasma samples. The use of plasma samples offers the important advantage of
144 allowing the simultaneous detection of biomarkers of infection with different pathogens in
145 the same specimen. This approach enables increased efficiency not only in the diagnosis of
146 concomitant infections or the differential diagnosis of infections with overlapping clinical
147 features in patients, but also in conducting epidemiological studies and surveillance activities
148 of different infectious diseases such as malaria and NTDs, including the integrated
149 monitoring of control interventions impact [30-32]. A further advantage is the possibility of
150 retrospective analysis of archived plasma samples for further investigations.

151 Despite the benefits offered by plasma assays for *S. haematobium* diagnosis, to the best of
152 our knowledge, a comparative evaluation of their diagnostic performance has not yet been
153 conducted in endemic populations. To this aim, we took advantage of archived plasma
154 samples collected during malariological surveys in an area of *S. haematobium* and malaria
155 co-endemicity in Burkina Faso [33].

156

157 **Methods**

158 *Study design*

159 The present study aimed at measuring plasma biomarkers of *S. haematobium* infection in
160 samples collected during a cross-sectional survey conducted among endemic populations
161 from Burkina Faso, and at performing a comparative evaluation of their diagnostic
162 performance.

163 The cross-sectional survey was conducted in August 2007 in two rural villages (Barkoumbilen
164 and Barkoundouba) of shrubby savannah areas of Burkina Faso northeast of the capital town
165 Ouagadougou, for malaria epidemiology purposes [34]. A 2 mL venous blood sample was
166 collected from each participant in ethylenediaminetetraacetic acid (EDTA) tubes). Plasma was
167 separated by centrifugation (3min at 2000 rpm), aliquoted and stored at -80°C until assays
168 were performed. The study area is endemic for *S. haematobium* [1, 33].

169 Assays have been performed on 406 archived plasma samples to measure the following
170 biomarkers: *Schistosoma* spp. Circulating Anodic Antigen (CAA), *S. haematobium* cell-free
171 circulating DNA (cfDNA), *S. mansoni* cfDNA, IgM and IgG against *S. haematobium* Soluble
172 Worm Adult Protein (SWAP) and Soluble Egg Antigen (SEA). The species-specific results of
173 cfDNA testing were used to confirm that the study area is endemic for *S. haematobium* only.

174 The evaluation of the diagnostic performance of the different biomarker tests was
175 conducted comparing the results to those of three different references (i.e. defining true
176 infection status): i) Circulating Anodic Antigen; ii) Composite Reference Standard; iii) Latent
177 Class Analysis.

178

179 *Ethics statement*

180 Study subjects or their guardians gave written informed consent for participation. The
181 original malaria epidemiological study received approval from the ethical committee of the
182 Ministry of Health of Burkina Faso (2007-048). The use of archived plasma samples for
183 schistosomiasis research received further approval from the ethical committee of the
184 Ministry of Health and Public Hygiene of Burkina Faso (2022-05-15).

185

186 *Circulating Anodic Antigen*

187 The Up-Converting Particle Lateral Flow (UCP-LF) assay was conducted in Leiden University
188 Medical Center, the Netherlands, to detect Circulating Anodic Antigen (CAA) in plasma
189 samples as previously described (SCAA20) [16, 35]. High Salt Lateral Flow (HSLF) buffer (100
190 mM HEPES pH 7.5, 270 mM NaCl, 0.5% v/v Tween-20, 1% w/v BSA, 50 μ L) was pipetted into
191 the wells of a 96-wells microplate. Each plasma sample (50 μ L) was mixed with an equal
192 volume of 4% trichloroacetic acid (TCA) and centrifuged for 5 minutes at 18,000 RCF to
193 separate the supernatant from the pellet. The supernatant (20 μ L) and a UCP solution (50 μ L)
194 containing reporter particles (400 nm $Y_2O_3:S:Yb^{3+},Er^{3+}$) conjugated with mouse monoclonal
195 anti-CAA antibody (25 μ g/mg) were pipetted in the microplate wells. After an incubation of
196 1 hour at 37°C with shaking (900 rpm), LF strips with a test line comprising 200 ng mouse
197 monoclonal anti-CAA antibody were added into the wells. A dilution series of a sample with
198 known CAA concentration (pg/ml) was included in the microplate and used as a standard
199 curve to quantify CAA concentrations and to validate the threshold of the assay (10 pg/ml).
200 Strips were incubated overnight and scanned with an UPCON reader (980 nm excitation, 540

201 nm emission; Labrox Oy, Turku, Finland) for analysis. A threshold of 10 pg/ml (SCAA20, wet
202 test format) was used to define CAA positivity [16, 35]. CAA levels were defined based on
203 concentration ranges as follows: level 0=0-9 pg/ml range; level 1=10-99 pg/ml range; level
204 2=100-999 pg/ml range; level 3=1000-9999 pg/ml range; level 4=10000-100000 pg/ml
205 range.

206

207 *Cell-free circulating DNA*

208 Cell free circulating DNA (cfDNA) was extracted from 100 µL plasma samples using the QIA
209 amp Min Elute cfDNA Mini Kit according to the manufacturer's protocol. Real Time PCR was
210 performed at the Bernard Nocht Institute for Tropical Medicine, Germany, to amplify and
211 detect *S. heamatobium* (*Dra1*) and *S. mansoni* (*Sm1-7*) target sequences (Sh-Forward Primer:
212 5'-GATCTCACCTATCAGACG AAAC-3', Sh-Reverse Primer: 5'-TCACAACGATACGACCAAC-3',
213 Sh-Probe: 5'-Joe-TGTTGGAAGZGCCTGTTTCGCAA-BHQ1-3'; Sm-Forward Primer: 5'-
214 CAACCGTTCTATGAA AATCGTTGT-3', Sm-Reverse Primer : 5'-CCA CGCTCTCGCAAATAATCT-3',
215 Sm-Probe: 5'-Fam-TCCGAAACCACTGGACGGATTTTTATGAT-BHQ1-3') as previously
216 described [21-22]. Primers and probe were included for the detection of Phocid herpesvirus
217 (PhHV) DNA as internal PCR control (PhHV—Forward Primer: 5' GGG CGA ATC ACA GAT TGA
218 ATC 3', PhHV—Reverse Primer: 5' GCG GTT CCA AAC GTA CCA A 3', PhHV—Probe: 5' Cy5.5-
219 TTT TTA TGT GTC CGC CAC CA-BBQ 3'). Briefly, the reaction was performed in a total volume
220 reaction of 25 µL containing 12.5 µl HotStarTaq Mastermix (Qiagen, Hilden, Germany), 5 mM
221 MgCl₂, 500 nM of each *Schistosoma* primer, 250 nM of each *Schistosoma* probe, 40 nM of
222 the PhHV primer, 50 nM of the PhHV probe, 1.425 µg of the PhHV DNA template, 0.04 µg/µl

223 bovine serum albumin and 5 μ L of DNA eluate. The amplification reaction (15 minutes at
224 95°C followed by 50 cycles of 15 seconds at 95°C and 60 seconds at 60°C with an initial
225 touchdown from 65°C to 60°C in the first 11 cycles) was conducted using the Corbett Rotor-
226 Gene 6000 (Qiagen) and results were analysed with the RotorGene 6000 Software v.7.87
227 (Qiagen). Samples with a clean sigmoid curve within the PCR cycles were considered positive.

228

229 *Specific immunoglobulins*

230 Specific IgM and IgG against *S. haematobium* Soluble Worm Adult Protein (SWAP) and
231 Soluble Egg Antigen (SEA) were measured by ELISA using an in house protocol adapted from
232 Mutapi and colleagues [27] as previously described [33]. Antigens were purchased from the
233 Theodor Bilharz Institute, Giza, Egypt. A volume of 100 μ L antigen (5 μ g/mL for SWAP and
234 10 μ g/mL for SEA) in coating buffer (0.5 M sodium carbonate pH 9.6) was added per well in
235 96-wells plates (Nunc Immunosorp), and plates were incubated overnight at 4°C. After 3
236 washings (PBS-0.03 % Tween 20, PBS-T), 200 μ L blocking buffer (5 % skimmed milk powder
237 in PBS/T) was added per well and plates incubated 2h at room temperature (RT). After 3
238 washings, plasma samples were added in duplicate in blocking buffer with a total volume of
239 100 μ L (1:200 dilution for IgM and 1:100 dilution for IgG) and plates were incubated 2h at RT.
240 After three washings 100 μ L HRP-anti-human-IgG (Dako) at 1:1000 dilution in PBS-T was
241 added and plates incubated for 2h at RT. After six washings 100 μ L OPD (Sigma) substrate
242 solution was added, and plates incubated for 20 min in the dark at RT. A volume of 25 μ L of
243 H₂SO₄ 1 M stop solution was added and plates were read with Synergy HT Biotek reader at
244 the absorbance of 492 nm. A standard curve consisting of a 5-point dilution series of a pool

245 of positive control (patients with positive result of urine filtration microscopy) samples was
246 included in each plate as well as a negative control consisting of a pool of negative control
247 (naïve blood donors) samples and a blank control containing no plasma. The OD value of
248 the blank control was subtracted from the OD values of test samples, and those were then
249 fitted to account for experimental variation using the standard curves (fitted OD, fOD). The
250 cut-off used for positivity was the mean absorbance plus 3 standard deviation of negative
251 control samples (cutoff = mean OD neg + 3SD neg). Logarithm transformation has been
252 applied to fOD values (logfOD) to normalise their distribution.

253

254 *Statistical analysis*

255 In reporting binary (i.e. positive/negative) test results, the proportion of positive results was
256 computed with its 95% Confidence Interval (CI), shown using barplots and compared
257 between population groups by logistic regression.

258 In reporting quantitative (i.e. antibody levels or antigen concentration) test results, the
259 distribution was shown using boxplots and compared between population groups by linear
260 regression. Correlation between quantitative test results was displayed using scatter plots
261 and assessed by Spearman test.

262 The diagnostic performance of each test has been evaluated by comparison of binary results
263 with three references: i) Circulating Anodic Antigen; ii) Composite Reference Standard; iii)
264 Latent Class Analysis. For each comparison, sensitivity and specificity with their respective
265 95% CI were computed, as well as overall agreement and Cohen's k statistics. Cohen's k was
266 interpreted as follows: values ≤ 0 as no agreement, 0.01–0.20 as none to slight, 0.21–0.40 as

267 fair, 0.41– 0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect
268 agreement.

269 CAA was chosen as a reference since it is a validated marker of infection [15-16].

270 A Composite Reference Standard (CRS) was defined as follows: a sample was considered
271 positive if one or both direct (i.e. CAA and/or cfDNA) test results were positive, while it was
272 considered negative if both direct tests results were negative. The rationale of the algorithm
273 is to define infection status based on direct markers tests, and it assumes that both CAA and
274 cfDNA have 100% specificity [36].

275 Latent Class Analysis (LCA) modelling with two clusters was used to define a binary
276 (positive/negative) LCA reference [26]. The model included all available manifest variables:
277 CAA (positive/negative), cfDNA (positive/negative), anti-SWAP IgM level (log₁₀-fOD), anti-
278 SWAP IgG level (log₁₀-fOD), anti-SEA IgG level (log₁₀-fOD), anti-SEA IgM level (log₁₀-fOD).
279 The LCA reference therefore defines infection status based on the results of all direct and
280 indirect biomarker tests.

281 Receiver Operating Characteristic (ROC) analysis was used to evaluate the ability of antibody
282 levels (log_fOD) to discriminate between positive and negative reference results, by
283 calculating Area Under Curve values and by computing specificity, sensitivity and overall
284 agreement for each possible cut-off value. An optimal cut-off value was identified by filtering
285 values associated with >75% agreement, sensitivity and specificity, ordering them from
286 higher to lower agreement, sensitivity and specificity, and selecting the top value. A cutoff
287 Antibody Index (AI) was calculated as the ratio between the value of the cutoff and the value
288 of the negative control.

289 All analyses were performed in STATA v13.00, except for the LCA analysis that was conducted
290 using using R v. 4.3.1 and its package *flexmix*.

291

292 **Results**

293 Real Time PCR did detect *S. haematobium* cfDNA in the study sample, but not *S. mansoni*
294 cfDNA (data not shown), as expected from the literature [1]. Therefore, it can be assumed
295 that CAA in this area is a product of *S. haematobium* and therefore a biomarker of urogenital
296 schistosomiasis. The proportion of positive results for each plasma biomarker of *S.*
297 *haematobium* infection is shown in Table 1. CAA and cfDNA tests result in an identical
298 proportion of positive subjects, equal to 29%. Specific antibody tests result in a higher
299 proportion of positive subjects, ranging from 47% to 72%, with anti-SEA Ig showing higher
300 positivity than anti-SWAP Ig.

301

302

303 **Table 1. Proportion of positive subjects for plasma biomarkers of *S. haematobium***
304 **infection.**

305 The table shows, for each plasma biomarker of *S. haematobium* infection, the number of
306 positive subjects (N+), the number of subjects in the study population (Ntot), and the
307 proportion of positive subjects (%) with its lower (LCL) and upper (UCL) 95% Confidence
308 Limits.

Marker	Positive subjects				
	N+	Ntot	Proportion+ (%)	LCL	UCL
CAA	118	406	29.1	24.8	33.7
cfDNA	118	406	29.1	24.8	33.7
anti-SWAP IgM	192	406	47.3	42.5	52.2
anti-SWAP IgG	223	406	54.9	50.0	59.7
anti-SEA IgM	292	406	71.9	67.3	76.1
anti-SEA IgG	282	406	69.5	64.8	73.8

309

310

311 The breadth of antibody response to *S. haematobium* (*Sh*) antigens (i.e. the total number of
312 specific Ig for which a positive result was observed) and the different patterns of positivity
313 are shown in Table 2. Overall, 15% of subjects were seronegative for anti-*Sh* Ig. Among
314 subjects who were seropositive for only one specific Ig (12%), the majority was positive for
315 anti-SEA IgG. Among subjects who were seropositive for two specific Ig (18%), the two most
316 and equally frequent combinations were anti-SWAP IgM/anti-SWAP IgG and anti-SWAP
317 IgG/anti-SEA IgG. Among subjects who were seropositive for three specific Ig (26%), the
318 majority was positive for all Ig except anti-SWAP IgM. Finally, about 29% of subjects were
319 positive for all four specific Ig. In order to investigate the diagnostic potential of indirect

320 markers compared to direct ones, the positivity of CAA and cfDNA direct markers according
 321 to the breadth of the anti-*Sh* Ig response was assessed by logistic regression analysis. It can
 322 be observed that both CAA (OR=2.4, 95%CI=1.9-3.0, p-value<0.001) and cfDNA (OR=2.6,
 323 95% CI=2.1-3.4, p-value<0.001) positivity increase significantly with the number of positive
 324 specific Ig (Figure 1).

325 **Table 2. Patterns of antibody response against *S. haematobium* antigens.**

326 The table shows the breadth of the antibody response to *S. haematobium* antigens
 327 (number of positive anti-*Sh* Ig) and the different positivity patterns of IgM and IgG
 328 responses to SWAP and SEA antigens, with their relative proportion (%) in the total study
 329 population.

Breadth		Pattern				Proportion (%)
anti- <i>Sh</i> Ig+ (N)	Proportion (%)	anti-SWAP		anti-SEA		
		IgM	IgG	IgM	IgG	
0	14.5					14.5
1	12.3					2.2
						0.3
						4.7
						5.2
2	17.5					5.9
						1.2
						1.5
						3.7
						5.2
						1.5
3	26.4					1.0
						6.2
						17.7
4	29.3					29.3
Total	100	Total				100

330

331

332 The formal evaluation of the diagnostic performance of the different biomarkers was
333 conducted by comparing each test results to those of three different references (i.e. "true"
334 infection status): i) Circulating Anodic Antigen (CAA); ii) Composite Reference Standard
335 (CRS); iii) Latent Class Analysis (LCA). For each comparison, sensitivity and specificity were
336 calculated as well as the overall agreement.

337

338 In comparison with CAA as the reference test (Table 3), cfDNA showed 73% sensitivity and
339 89% specificity, with a Cohen's k of 0.64, indicating substantial agreement. Indeed, despite
340 resulting in an identical proportion of positive samples, the two tests did not yield identical
341 results (Supplementary Figure 1). The comparison of CAA and cfDNA results stratified by
342 CAA level shows that the proportion of "false negative" cfDNA results decreases significantly
343 with increasing CAA levels (OR=0.23, 95% CI=0.17-0.31, p-value<0.001; Figure 2). Among
344 specific antibodies, Cohen's k ranged from 0.09 to 0.37, indicating none to fair agreement,
345 with the best performance being observed for anti-SWAP IgG, showing 88% sensitivity and
346 59% specificity.

347

348 **Table 3. Diagnostic performance of plasma biomarkers compared to Circulating**
 349 **Anodic Antigen.**

350 The table shows, for each plasma biomarker of *S. haematobium* infection, the sensitivity
 351 (Se) and specificity (Sp) with their lower (LCL) and upper (UCL) 95% Confidence Limits, the
 352 overall agreement and the Cohen’s K value, when compared to Circulating Anodic Antigen
 353 as the reference.

Marker	Circulating Anodic Antigen							
	Se	LCL	UCL	Sp	LCL	UCL	Agreement	Cohen's K
CAA	-	-	-	-	-	-	-	-
cfDNA	73%	65%	81%	89%	85%	93%	84%	0.62
anti-SWAP IgM	55%	46%	64%	56%	50%	62%	56%	0.09
anti-SWAP IgG	88%	82%	94%	59%	53%	64%	67%	0.37
anti-SEA IgM	94%	90%	98%	37%	32%	43%	54%	0.22
anti-SEA IgG	95%	91%	99%	41%	35%	47%	57%	0.25

354

355

356 A CRS was built using an algorithm that classified a sample as positive if it exhibits positive
 357 results of either or both direct marker tests (CAA+ OR cfDNA+), and as negative if they
 358 exhibit negative results of both direct marker tests (CAA- AND cfDNA-), irrespectively of the
 359 results of indirect marker tests. This CRS resulted in a 37% proportion of positive subjects
 360 (data not shown). In comparison with the CRS (Table 4), both CAA and cfDNA showed 79%
 361 sensitivity and 100% specificity (as expected), with an overall almost perfect agreement (92%,
 362 Cohen’s K=0.82). Among specific antibodies, Cohen’s k ranged from 0.11 to 0.43, indicating
 363 slight to moderate agreement, and once again the best performance was observed for anti-
 364 SWAP IgG, showing 85% sensitivity and 63% specificity.

365 **Table 4. Diagnostic performance of plasma biomarkers compared to a Composite**
 366 **Reference Standard.**

367 The table shows, for each plasma biomarker of *S. haematobium* infection, the sensitivity (Se)
 368 and specificity (Sp) with their lower (LCL) and upper (UCL) 95% Confidence Limits, the overall
 369 agreement and the Cohen's K value, when compared to a Composite Reference Standard.

Marker	Composite Reference Standard							
	Se	LCL	UCL	Sp	LCL	UCL	Agreement	Cohen's K
CAA	79%	72%	85%	100%	100%	100%	92%	0.82
cfDNA	79%	72%	85%	100%	100%	100%	92%	0.82
anti-SWAP IgM	55%	47%	63%	57%	51%	63%	56%	0.11
anti-SWAP IgG	85%	79%	90%	63%	57%	68%	71%	0.43
anti-SEA IgM	94%	90%	98%	41%	35%	47%	61%	0.29
anti-SEA IgG	94%	90%	98%	45%	39%	51%	63%	0.33

370
 371 Finally, result of each biomarker were compared with results of LCA modelling (Table 5),
 372 where a sample was classified as positive or negative based on all available biomarker data,
 373 and that resulted in a 35% proportion of positive subjects (data not shown). In comparison
 374 with the LCA, both CAA and cfDNA showed substantial agreement, with Cohen's k equal to
 375 0.62 and 0.75 respectively. Among specific antibodies, Cohen's k ranged from 0.15 to 0.55,
 376 indicating slight to moderate agreement. Consistently with previous comparisons, the best
 377 performance was observed for anti-SWAP IgG, showing 97% sensitivity and 67% specificity.

378 **Table 5. Diagnostic performance of plasma biomarkers compared to Latent Class**
379 **Analysis classification.**

380 The table shows, for each plasma biomarker of *S. haematobium* infection, the sensitivity (Se)
381 and specificity (Sp) with their lower (LCL) and upper (UCL) 95% Confidence Limits, the overall
382 agreement and the Cohen's K value, when compared to Latent Class Analysis classification.

Marker	Latent Class Analysis							
	Se	LCL	UCL	Sp	LCL	UCL	Agreement	Cohen's K
CAA	67%	60%	75%	92%	89%	95%	83%	0.62
cfDNA	76%	69%	83%	97%	94%	99%	89%	0.75
anti-SWAP IgM	58%	50%	66%	58%	52%	64%	58%	0.15
anti-SWAP IgG	95%	92%	99%	67%	61%	73%	77%	0.55
anti-SEA IgM	99%	97%	100%	43%	37%	49%	63%	0.34
anti-SEA IgG	100%	100%	100%	47%	41%	53%	66%	0.39

383

384 Receiver Operating Curve (ROC) analysis was conducted to further evaluate the diagnostic
385 performance of *S. haematobium* specific antibodies. The Area Under Curve (AUC) statistics,
386 a measure of the ability of a marker to correctly classify positive and negative cases as
387 defined by a reference standard, was computed for each antibody test against the three
388 references (CAA, CRS, LCA). The comparison of AUC allows to identify the marker showing
389 the best diagnostic performance: the highest AUC value was observed for anti-SEA IgG,
390 followed closely by anti-SWAP IgG, for each reference (Table 6; Supplementary Figures 2-4).

391

392 **Table 6. Diagnostic performance of antibody tests resulting from ROC analysis.**

393 The table shows, for each *S.haematobium* antibody test, the Area Under Curve (AUC)
394 resulting from ROC analysis conducted to evaluate the diagnostic performance compared
395 to Circulating Anodic Antigen (CAA), Composite Reference Standard (CRS), and Latent Class
396 Analysis classifications.

Marker	Area Under Curve (AUC)		
	CAA	CRS	LCA
anti-SWAP IgM	0.567	0.597	0.635
anti-SWAP IgG	0.826	0.832	0.915
anti-SEA IgM	0.765	0.796	0.861
anti-SEA IgG	0.878	0.901	0.995

397

398 For anti-SWAP and anti-SEA IgG, ROC analysis was employed for further comparison with
399 CAA to generate Sensitivity/Specificity plots (Figure 3), which show that selecting a higher
400 cutoff value compared to the analytical one would result in better diagnostic performances.
401 For instance, for anti-SWAP IgG, a cut-off of 0.196 log(fOD) corresponding to a 2.3 Antibody
402 Index (AI) would result in 75% sensitivity, 76% specificity and 76% agreement. Similarly, for
403 anti-SEA IgG, a cut-off of 0.242 log(fOD) corresponding to a 4.5 AI would result in 82%
404 sensitivity, 80% specificity and 81% agreement (data not shown). Also, the distribution of
405 antibody levels according to CAA positivity was investigated, as well as the correlation
406 between antibody levels and CAA concentration ranges. The distribution of antibody levels
407 was significantly higher in subjects that were positive to CAA than in negative subjects, for
408 both anti-SWAP IgG ($\text{Exp}\beta=15.3$, 95%CI=9.8-23.8, p-value<0.001; Figure 4, left panel) and
409 anti-SEA IgG ($\text{Exp}\beta=13.3$, 95%CI=9.4-18.8, p-value<0.001; Figure 4, right panel). Finally, a

410 scarce albeit significant positive correlation was observed between antibody levels and CAA
411 concentration, both for anti-SWAP IgG (Spearman P-value<0.001, rho=0.425; Figure 5 left
412 panel) and anti-SEA IgG (Spearman P-value<0.001, rho=0.437; Figure 5, right panel).

413

414 **Discussion**

415 In summary, the measurement of plasma biomarkers of *S. haematobium* infection among
416 406 subjects living in rural endemic villages of Burkina Faso, West Africa, has shown that
417 both CAA and cfDNA testing result in a 29% proportion of positive samples. A 29%
418 prevalence of urogenital schistosomiasis in this area confirms an estimate for Burkina Faso
419 based on systematic review of survey data and geostatistical modelling (26.3%) [1]. However,
420 it likely represents an underestimation, as suggested by the observation that CRS and LCA
421 show a proportion of positive subjects of 37% and 35%, respectively. Indeed, despite an
422 identical proportion of positive samples identified by CAA and cfDNA testing, the two tests
423 did not yield identical results. Discordant CAA negative/cfDNA positive results could be
424 attributed to differences in the stage specificity of the two markers, with cfDNA detecting all
425 stages including larval ones while CAA detecting adults [37], and/or by recently cleared
426 infections with cfDNA persisting in circulation longer than CAA [38]. On the other hand,
427 discordant CAA positive/cfDNA negative results could be attributed to a suboptimal cfDNA
428 sensitivity at low CAA concentrations because of an insufficient plasma volume used for
429 nucleic acid extraction in this study (1000µl of plasma was used in a previous work [22]
430 compared to the 100µl used in the present study), an hypothesis supported by the

431 observation that the proportion of “false negative” cfDNA results decreases significantly with
432 increasing CAA levels. Despite some discordant results, there was a substantial agreement
433 between CAA and cfDNA testing, along with a comparable agreement with the results of
434 CRS and LCA. Taken together, the identical proportion of positive samples identified by the
435 two tests, and the substantial agreement of the results, indicate that CAA and cfDNA are
436 equivalent good plasma biomarkers of infection in areas of *S. haematobium* endemicity.

437 As expected, specific antibody testing resulted in a much higher proportion of positive
438 samples (47%-72% range), as the presence of specific antibodies might reflect not only
439 current infection but past exposure to the parasite. Interestingly, it was observed that the
440 breadth of the antibody response to *S. haematobium* was positively associated with both
441 CAA and cfDNA positivity, indicating that subjects harbouring antibodies against multiple *S.*
442 *haematobium* antigens are more likely to be currently infected. The analysis of individual
443 responses has shown that IgG against SWAP and SEA exhibit a higher agreement with the
444 three references (CAA, CRS and LCA) compared to IgM. When compared to CAA, ROC
445 analysis confirmed a better ability of IgG to distinguish positive and negative subjects, and
446 showed that higher cutoff values result in greatly enhanced specificity and overall diagnostic
447 performance of these indirect biomarkers. Indeed, IgG levels were significantly higher in CAA
448 positive than CAA negative subjects, indicating that antibody levels are increased in subjects
449 with current infection compared to subjects with past exposure, and highlighting the
450 relevance of the choice of appropriate cutoff values for accurate detection of infection.
451 However, only a moderate correlation between IgG antibody levels and CAA concentration

452 was observed, indicating that IgG levels cannot be used as markers of *S. haematobium*
453 infection intensity.

454 One limitation of the present study is the lack of results from urine filtration microscopy, as
455 urine specimens were not collected during the original investigation survey. Also, the
456 antibody response to CAP was not investigated, as this antigen could not be procured at the
457 time of analysis. Since CAP is a cercarial antigen, data would have been beneficial for
458 interpreting discordant results between cfDNA and CAA testing, by either supporting or
459 refusing the hypothesis that very recent infections with larval stages would be detected by
460 cfDNA but not CAA.

461 Despite the above limitations, the comparative evaluation of plasma biomarkers presented
462 herein represents, to our knowledge, the first conducted among endemic populations. The
463 data provide valuable insights that can inform the choice of testing to be employed in areas
464 endemic for urogenital schistosomiasis, depending on the purpose, context, needs and
465 available laboratory resources. For diagnostic “test-to-treat” purposes, when infection with
466 *S. haematobium* is suspected, either CAA or cfDNA testing can be performed for
467 confirmation, even in the absence of urine filtration microscopy, while anti-SWAP and anti-
468 SEA IgG testing could be performed for supporting evidence. A similar strategy is currently
469 recommended in non-endemic countries for the diagnosis of schistosomiasis [39]. It is
470 noteworthy that only cfDNA is a species-specific marker, and therefore CAA positive results
471 do not exclude an infection with other *Schistosoma* species. However, only CAA provides a
472 quantitative measurement (i.e. CAA concentration) associated with worm burden that can
473 be used for follow-up of treated patients [40]. Likewise, for epidemiological investigations,

474 either CAA or cfDNA testing can be performed to assess infection in areas of *S. haematobium*
475 endemicity depending on laboratory resources, since they are equivalent good markers. As
476 mentioned above, it should also be considered that only cfDNA testing would provide a
477 confirmation of the species while only CAA testing results can be analyzed as a quantitative
478 variable which might be an advantage for association studies. Finally, for surveillance
479 purposes, once the appropriate cut-off has been established for a given epidemiological
480 context to ensure optimal agreement with markers of current infection, anti-SWAP or anti-
481 SEA IgG testing could be either employed, with the important advantages of allowing
482 multiplexing with other antibody tests as well as automation.

483 The availability of different accurate diagnostic tests for *S. haematobium* infection based on
484 the detection of plasma biomarkers represents a significant development in the control of
485 urogenital schistosomiasis in endemic areas.

486

487 **Authors contributions**

488 MO, JH, SH, VRF, DW, RR and PH conducted the experiments. YK and IN coordinated the
489 cross-sectional survey. MF and LB performed Latent Class Analysis. GJvD, PC, DF, DM, FB and
490 VM designed experiments and contributed experimental resources. FB, DM and VDM
491 designed the study. VDM performed data analyses and wrote the manuscript. All authors
492 revised and approved the final version of the manuscript.

493

494

495 **Funding**

496 No specific funding was obtained to conduct the research herein presented. M Ouedraogo
497 was supported by the PhD School in Microbiology, Infectious Diseases and Public Health,
498 Sapienza University of Rome. VD Mangano was supported by the University of Pisa and the
499 Minister of University and Research. D Fusco was supported by the German Centre for
500 Infection.

501

502 **Acknowledgments**

503 The authors would like to thank participants for making the study possible; physicians,
504 nurses, laboratory technicians, data management staff at Centre National de Recherche et
505 Formation sur le Paludisme for their skilled work; Zeno Bisoffi at Centre for Tropical Diseases
506 in Negrar, Italy, for contributing sera samples of patients infected with *S. haematobium*;
507 Carlota Dobano, Gemma Moncunill and colleagues at Barcelona Institute for Global Health,
508 Spain, for critical discussion of the results; the Italian Network for Neglected Tropical
509 Diseases for promoting research, control and advocacy activities for the fight against NTDs.

510

511 **Data availability**

512 Data have been deposited in the Repository Figshare and are (DOI:
513 10.6084/m9.figshare.25311364).

514

515 **REFERENCES**

516

- 517 1. Lai YS, Biedermann P, Ekpo UF, Garba A, Mathieu E, Midzi N, Mwinzi P, N'Goran EK,
518 Raso G, Assaré RK, Sacko M, Schur N, Talla I, Tchuente LA, Touré S, Winkler MS,
519 Utzinger J, Vounatsou P. Spatial distribution of schistosomiasis and treatment needs
520 in sub-Saharan Africa: a systematic review and geostatistical analysis. *Lancet Infect*
521 *Dis.* 2015 Aug;15(8):927-40. doi: 10.1016/S1473-3099(15)00066-3.
- 522 2. WHO. 2020 Ending the neglect to attain the sustainable development goals: a road
523 map for neglected tropical diseases 2021–2030. Geneva, Switzerland: World Health
524 Organization.
- 525 3. WHO. 2022 WHO guideline on control and elimination of human schistosomiasis.
526 Geneva, Switzerland: World Health Organization.
- 527 4. Kincaid-Smith J, Tracey A, de Carvalho Augusto R, Bulla I, Holroyd N, Rognon A, Rey
528 O, Chaparro C, Oleaga A, Mas-Coma S, Allienne JF, Grunau C, Berriman M, Boissier J,
529 Toulza E. Morphological and genomic characterisation of the *Schistosoma* hybrid
530 infecting humans in Europe reveals admixture between *Schistosoma haematobium*
531 and *Schistosoma bovis*. *PLoS Negl Trop Dis.* 2021 Dec 23;15(12):e0010062. doi:
532 10.1371/journal.pntd.0010062.
- 533 5. Rothe C, Zimmer T, Schunk M, Wallrauch C, Helfrich K, Gültekin F, Bretzel G, Allienne
534 JF, Boissier J. Developing Endemicity of Schistosomiasis, Corsica, France. *Emerg*
535 *Infect Dis.* 2021 Jan;27(1):319-21. doi: 10.3201/eid2701.204391.
- 536 6. Salas-Coronas J, Bargues MD, Lozano-Serrano AB, Artigas P, Martínez-Ortí A, Mas-
537 Coma S, Merino-Salas S, Abad Vivas-Pérez JI. Evidence of autochthonous
538 transmission of urinary schistosomiasis in Almeria (southeast Spain): An outbreak
539 analysis. *Travel Med Infect Dis.* 2021 Nov-Dec;44:102165. doi:
540 10.1016/j.tmaid.2021.102165.
- 541 7. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. *Lancet.* 2014
542 Jun 28;383(9936):2253-64. doi: 10.1016/S0140-6736(13)61949-2
- 543 8. Gabrielli AF & Garba Djirmay A, 2022. Schistosomiasis. In: *Encyclopedia of Infection*
544 *and Immunity, Volume 2, 2022, Pages 666–677, Elsevier 2022.*

- 545 9. Othman A., El Ridi R. Schistosomiasis. In: F. Bruschi (ed.), Helminth Infections and
546 their Impact on Global Public Health, 2nd edition, Springer-Verlag Wien 2022.
- 547 10. Hotez PJ, Engels D, Gyapong M, Ducker C, Malecela MN. Female Genital
548 Schistosomiasis. N Engl J Med. 2019 Dec 26;381(26):2493-2495. doi:
549 10.1056/NEJMp1914709.
- 550 11. Hotez PJ, Harrison W, Fenwick A, Bustinduy AL, Ducker C, Sabina Mbabazi P, Engels
551 D, Floerecke Kjetland E. Female genital schistosomiasis and HIV/AIDS: Reversing the
552 neglect of girls and women. PLoS Negl Trop Dis. 2019 Apr 4;13(4):e0007025. doi:
553 10.1371/journal.pntd.0007025
- 554 12. WHO (1991) Basic laboratory methods in medical parasitology. In: Basic Malaria
555 Microscopy, Part I, World Health Organization, Geneva.
- 556 13. Knopp S, Ame SM, Hattendorf J, Ali SM, Khamis IS, Bakar F, et al. Urogenital
557 schistosomiasis elimination in Zanzibar: accuracy of urine filtration and haematuria
558 reagent strips for diagnosing light intensity *Schistosoma haematobium* infections.
559 Parasit Vectors. 2018;11(1):552
- 560 14. Ochodo EA, Gopalakrishna G, Spek B, Reitsma JB, van Lieshout L, Polman K,
561 Lamberton P, Bossuyt PM, Leeflang MM. Circulating antigen tests and urine reagent
562 strips for diagnosis of active schistosomiasis in endemic areas. Cochrane Database
563 Syst Rev. 2015 Mar 11;2015(3):CD009579. doi: 10.1002/14651858.CD009579.pub2.
- 564 15. Knopp S, Corstjens PL, Koukounari A, Cercamondi CI, Ame SM, Ali SM, de Dood CJ,
565 Mohammed KA, Utzinger J, Rollinson D, van Dam GJ. PLoS Negl Trop Dis. Sensitivity
566 and Specificity of a Urine Circulating Anodic Antigen Test for the Diagnosis of
567 *Schistosoma haematobium* in Low Endemic Settings. 2015 May 14;9(5):e0003752.
568 doi: 10.1371/journal.pntd.0003752.
- 569 16. Corstjens PLAM, de Dood CJ, Knopp S, Clements MN, Ortu G, Umulisa I, Ruberanziza
570 E, Wittmann U, Kariuki T, LoVerde P, Secor WE, Atkins L, Kinung'hi S, Binder S,
571 Campbell CH, Colley DG, van Dam GJ. Circulating Anodic Antigen (CAA): A Highly
572 Sensitive Diagnostic Biomarker to Detect Active *Schistosoma* Infections-

- 573 Improvement and Use during SCORE. *Am J Trop Med Hyg.* 2020 Jul;103(1_Suppl):50-
574 57. doi: 10.4269/ajtmh.19-0819.
- 575 17. Ullah H, Arbab S, Li K, Khan MIU, Qadeer A, Muhammad N. Schistosomiasis related
576 circulating cell-free DNA: A useful biomarker in diagnostics. *Mol Biochem Parasitol.*
577 2022 Sep;251:111495. doi: 10.1016/j.molbiopara.2022.111495.
- 578 18. Cnops L, Soentjens P, Clerinx J, Van Esbroeck M. A *Schistosoma haematobium*-
579 specific real-time PCR for diagnosis of urogenital schistosomiasis in serum samples
580 of international travelers and migrants. *PLoS Negl Trop Dis.* 2013 Aug 29;7(8):e2413.
581 doi: 10.1371/journal.pntd.0002413.
- 582 19. Guegan H, Fillaux J, Charpentier E, Robert-Gangneux F, Chauvin P, Guemas E,
583 Boissier J, Valentin A, Cassaing S, Gangneux JP, Berry A, Iriart X. Real-time PCR for
584 diagnosis of imported schistosomiasis. *PLoS Negl Trop Dis.* 2019 Sep
585 11;13(9):e0007711. doi: 10.1371/journal.pntd.0007711.
- 586 20. Keller D, Rothen J, Dangy JP, Saner C, Daubenberger C, Allan F, Ame SM, Ali SM,
587 Kabole F, Hattendorf J, Rollinson D, Seyfarth R, Knopp S. Performance of a real-time
588 PCR approach for diagnosing *Schistosoma haematobium* infections of different
589 intensity in urine samples from Zanzibar. *Infect Dis Poverty.* 2020 Sep 4;9(1):128. doi:
590 10.1186/s40249-020-00726-y.
- 591 21. Frickmann H, Lunardon LM, Hahn A, Loderstädt U, Lindner AK, Becker SL,
592 Mockenhaupt FP, Weber C, Tannich E. Evaluation of a duplex real-time PCR in
593 human serum for simultaneous detection and differentiation of *Schistosoma*
594 *mansoni* and *Schistosoma haematobium* infections - cross-sectional study. *Travel*
595 *Med Infect Dis.* 2021 May-Jun;41:102035. doi: 10.1016/j.tmaid.2021.102035.
- 596 22. Gruninger SK, Rasamoelina T, Rakotoarivelo RA, Razafindrakoto AR, Rasolojaona ZT,
597 Rakotozafy RM, Soloniaina PR, Rakotozandrindrainy N, Rausche P, Doumbia CO,
598 Jaeger A, Zerbo A, von Thien H, Klein P, van Dam G, Tannich E, Schwarz NG, Lorenz
599 E, May J, Rakotozandrindrainy R, Fusco D. Prevalence and risk distribution of
600 schistosomiasis among adults in Madagascar: a cross-sectional study. *Infect Dis*
601 *Poverty.* 2023 Apr 25;12(1):44. doi: 10.1186/s40249-023-01094-z.

- 602 23. Hinz R, Schwarz NG, Hahn A, Frickmann H. Serological approaches for the diagnosis
603 of schistosomiasis - A review. *Mol Cell Probes*. 2017 Feb;31:2-21. doi:
604 10.1016/j.mcp.2016.12.003. Epub 2016 Dec 13.
- 605 24. Santano R, Rubio R, Grau-Pujol B, Escola V, Muchisse O, Cuamba I, Vidal M, Ruiz-
606 Olalla G, Aguilar R, Gandasegui J, Demontis M, Jamine JC, Cossa A, Sacoor C, Cano J,
607 Izquierdo L, Chitnis CE, Coppel RL, Chauhan V, Cavanagh D, Dutta S, Angov E, van
608 Lieshout L, Zhan B, Muñoz J, Dobaño C, Moncunill G. Evaluation of antibody
609 serology to determine current helminth and *Plasmodium falciparum* infections in a
610 co-endemic area in Southern Mozambique. *PLoS Negl Trop Dis*. 2022 Jun
611 21;16(6):e0010138. doi: 10.1371/journal.pntd.0010138.
- 612 25. Kinkel HF, Dittrich S, Bäumer B, Weitzel T. Evaluation of eight serological tests for
613 diagnosis of imported schistosomiasis. *Clin Vaccine Immunol*. 2012 Jun;19(6):948-53.
614 doi: 10.1128/CVI.05680-11
- 615 26. Beltrame A, Guerriero M, Angheben A, Gobbi F, Requena-Mendez A, Zammarchi L,
616 Formenti F, Perandin F, Buonfrate D, Bisoffi Z. PLoS Accuracy of parasitological and
617 immunological tests for the screening of human schistosomiasis in immigrants and
618 refugees from African countries: An approach with Latent Class Analysis. *Negl Trop*
619 *Dis*. 2017 Jun 5;11(6):e0005593. doi: 10.1371/journal.pntd.0005593
- 620 27. Mutapi F, Ndhlovu PD, Hagan P, Woolhouse ME. A comparison of humoral
621 responses to *Schistosoma haematobium* in areas with low and high levels of
622 infection. *Parasite Immunol*. 1997 Jun;19(6):255-63. doi: 10.1046/j.1365-
623 3024.1997.d01-206.x.
- 624 28. Pearson MS, Tedla BA, Mekonnen GG, Proietti C, Becker L, Nakajima R, Jasinskas A,
625 Doolan DL, Amoah AS, Knopp S, Rollinson D, Ali SM, Kabole F, Hokke CH, Adegnika
626 AA, Field MA, van Dam G, Corstjens PLAM, Mduluza T, Mutapi F, Oeuvray C, Greco
627 B, Chaiyadet S, Laha T, Cai P, McManus DP, Bottazzi ME, Felgner PL, Sotillo J, Loukas
628 A. Immunomics-guided discovery of serum and urine antibodies for diagnosing
629 urogenital schistosomiasis: a biomarker identification study. *Lancet Microbe*. 2021
630 Nov;2(11):e617-e626. doi: 10.1016/S2666-5247(21)00150-6.


- 631 29. Mekonnen GG, Tedla BA, Pearson MS, Becker L, Field M, Amoah AS, van Dam G,
632 Corstjens PLAM, Mdluza T, Mutapi F, Loukas A, Sotillo J. Characterisation of
633 tetraspanins from *Schistosoma haematobium* and evaluation of their potential as
634 novel diagnostic markers. *PLoS Negl Trop Dis*. 2022 Jan 24;16(1):e0010151. doi:
635 10.1371/journal.pntd.0010151.
- 636 30. Lammie PJ, Moss DM, Brook Goodhew E, Hamlin K, Krolewiecki A, West SK, Priest
637 JW. Development of a new platform for neglected tropical disease surveillance. *Int J*
638 *Parasitol*. 2012 Aug;42(9):797-800. doi: 10.1016/j.ijpara.2012.07.002
- 639 31. Arnold BF, van der Laan MJ, Hubbard AE, Steel C, Kubofcik J, Hamlin KL, Moss DM,
640 Nutman TB, Priest JW, Lammie PJ. Measuring changes in transmission of neglected
641 tropical diseases, malaria, and enteric pathogens from quantitative antibody levels.
642 *PLoS Negl Trop Dis*. 2017 May 19;11(5):e0005616. doi:
643 10.1371/journal.pntd.0005616.
- 644 32. Chan Y, Fornace K, Wu L, Arnold BF, Priest JW, Martin DL, Chang MA, Cook J,
645 Stresman G, Drakeley C. Determining seropositivity-A review of approaches to
646 define population seroprevalence when using multiplex bead assays to assess
647 burden of tropical diseases. *PLoS Negl Trop Dis*. 2021 Jun 28;15(6):e0009457. doi:
648 10.1371/journal.pntd.0009457.
- 649 33. Mangano VD, Bianchi C, Ouedraogo M, Kabore Y, Corran P, Silva N, Sirima SB, Nebie
650 I, Bruschi F, Modiano D. Antibody response to *Schistosoma haematobium* and other
651 helminth species in malaria-exposed populations from Burkina Faso. *Acta Trop*. 2020
652 May;205:105381. doi: 10.1016/j.actatropica.2020.105381.
- 653 34. Mangano VD, Kabore Y, Bougouma EC, Verra F, Sepulveda N, Bisseye C,
654 Santolamazza F, Avellino P, Tiono AB, Diarra A, Nebie I, Rockett KA, Sirima SB,
655 Modiano D; MalariaGEN Consortium. Novel Insights Into the Protective Role of
656 Hemoglobin S and C Against *Plasmodium falciparum* Parasitemia. *J Infect Dis*. 2015
657 Aug 15;212(4):626-34. doi: 10.1093/infdis/jiv098.
- 658 35. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, Nyakundi RK,
659 Loverde PT, Abrams WR, Tanke HJ, Van Lieshout L, Deelder AM, Van Dam GJ. Tools

- 660 for diagnosis, monitoring and screening of *Schistosoma* infections utilizing lateral-
661 flow based assays and upconverting phosphor labels. *Parasitology*. 2014
662 Dec;141(14):1841-55. doi: 10.1017/S0031182014000626.
- 663 36. Hoekstra PT, Madinga J, Lutumba P, van Grootveld R, Brienen EAT, Corstjens PLAM,
664 van Dam GJ, Polman K, van Lieshout L. Diagnosis of Schistosomiasis without a
665 Microscope: Evaluating Circulating Antigen (CCA, CAA) and DNA Detection Methods
666 on Banked Samples of a Community-Based Survey from DR Congo. *Trop Med Infect*
667 *Dis*. 2022 Oct 19;7(10):315. doi: 10.3390/tropicalmed7100315.
- 668 37. Weerakoon KG, Gordon CA, McManus DP. DNA Diagnostics for Schistosomiasis
669 Control. *Trop Med Infect Dis*. 2018 Aug 1;3(3):81. doi: 10.3390/tropicalmed303008
- 670 38. Guegan H, Fillaux J, Charpentier E, Robert-Gangneux F, Chauvin P, Guemas E,
671 Boissier J, Valentin A, Cassaing S, Gangneux JP, Berry A, Iriart X. Real-time PCR for
672 diagnosis of imported schistosomiasis. *PLoS Negl Trop Dis*. 2019 Sep
673 11;13(9):e0007711. doi: 10.1371/journal.pntd.0007711.
- 674 39. Comelli A, Genovese C, Gobbi F, Brindicci G, Capone S, Corpolongo A, Crosato V,
675 Mangano VD, Marrone R, Merelli M, Prato M, Santoro CR, Scarso S, Vanino E,
676 Marchese V, Antinori S, Mastroianni C, Raglio A, Bruschi F, Minervini A, Donà D,
677 Garazzino S, Galli L, Lo Vecchio A, Galli A, Dragoni G, Cricelli C, Colacurci N, Ferrazzi
678 E, Pieralli A, Montresor A, Richter J, Calleri G, Bartoloni A, Zammarchi L.
679 Schistosomiasis in non-endemic areas: Italian consensus recommendations for
680 screening, diagnosis and management by the Italian Society of Tropical Medicine
681 and Global Health (SIMET), endorsed by the Committee for the Study of
682 Parasitology of the Italian Association of Clinical Microbiologists (CoSP-AMCLI), the
683 Italian Society of Parasitology (SoIPa), the Italian Society of Gastroenterology and
684 Digestive Endoscopy (SIGE), the Italian Society of Gynaecology and Obstetrics
685 (SIGO), the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV),
686 the Italian Society of General Medicine and Primary Care (SIMG), the Italian Society
687 of Infectious and Tropical Diseases (SIMIT), the Italian Society of Pediatrics (SIP), the

688 Italian Society of Paediatric Infectious Diseases (SITIP), the Italian Society of Urology
689 (SIU). *Infection*. 2023 Oct;51(5):1249-1271. doi: 10.1007/s15010-023-02050-7.
690 40. Tamarozzi F, Ursini T, Hoekstra PT, Silva R, Costa C, Gobbi F, Monteiro GB, Motta L,
691 van Dam GJ, Corstjens PL, van Lieshout L, Buonfrate D. Evaluation of microscopy,
692 serology, circulating anodic antigen (CAA), and eosinophil counts for the follow-up
693 of migrants with chronic schistosomiasis: a prospective cohort study. *Parasit Vectors*.
694 2021 Mar 9;14(1):149. doi: 10.1186/s13071-021-04655-z.
695
696

697 **FIGURES**

698 **Figure 1. CAA and cfDNA positivity according to the breadth of the antibody**
699 **response to *S. haematobium* antigens.**



700


701 The figure shows the proportion of subjects showing results to CAA (blue) and cfDNA (green)
702 testing according to the breadth of the antibody response to *S. haematobium* antigens. Bars
703 represent proportion and whiskers represent the standard error of the proportion.

704

705

706 **Figure 2. Proportion of cfDNA negative results according to CAA levels.**

707




708

709 The figure shows the proportion of negative results according to CAA levels, i.e.
710 concentration ranges. Bars represent proportion and whiskers represent the standard error
711 of the proportion.

712

713

714 **Figure 3. Cutoff levels of anti-SWAP and anti-SEA IgG and diagnostic performance**
715 **compared to Circulating Anodic Antigen.**




716

717 The figure shows the plot of sensitivity (blue) and specificity (red) compared to Circulating
718 Anodic Antigen for each cutoff value of anti-SWAP IgG (left panel) and anti-SEA IgG (right
719 panel). The grey vertical line indicates the analytical cutoff.

720

721 **Figure 4. Distribution of anti-SWAP and anti-SEA IgG levels according to Circulating**
722 **Anodic Antigen positivity.**

723




724

725 The figure shows the boxplot distribution of anti-SWAP (left panel) and anti-SEA (right panel)
726 IgG levels according to Circulating Anodic Antigen (CAA) positivity (negative subjects, Neg;
727 positive subjects; Pos). The horizontal line represents the 50% percentile (median), the box
728 lower and upper limits represent the 25% and 75% percentiles respectively, and lower and
729 upper whiskers represent the 5% and 95% percentiles respectively, while the dots are outliers
730 of the distribution.

731

732


733 **Figure 5. Correlation of anti-SWAP and anti-SEA IgG levels with Circulating Anodic**
734 **Antigen concentration.**



735
736 The figure shows scatterplots illustrating the correlation of anti-SWAP IgG levels (log fOD;
737 left panel) and anti-SEA IgG levels (log fOD; right panel) with CAA concentration (log pm/ml).
738 Dots represent actual data points, the line represent the fitted data, and the grey area
739 represent the 95% confidence interval of the fitted line.

740
741
742

743 **Figure 6. Sensitivity and specificity of *S. haematobium* plasma biomarkers compared**
744 **to Circulating Anodic Antigen, Composite Reference Standard and Latent Class**
745 **Analysis.**



746

747 The figure shows forest plots of sensitivity (blue) and specificity (red) of different *S.*
748 *haematobium* plasma biomarkers compared to Circulating Anodic Antigen (CAA, left
749 panel), Composite Reference Standard (CRS, mid panel) and Latent Class Analysis (LCA,
750 right panel). Dots represent the estimate and whiskers represent the 95%CI of the estimate.

751